HHS Secretary Orders Alzheimer’s Drug Price be Reassessed

Response to Medicare’s announcement of Aduhelm price hike.

Secretary of Health and Human Services Xavier Becerra ordered a reassessment of Medicare’s proposed pricing for Aduhelm on Monday. The Alzheimer’s drug had dropped in price due to pressure placed on President Biden’s administration, but Medicare still announced a 14.5% increase in monthly premium, raising the price from $148.50 to $170.10.

“Today I’m instructing the Centers for Medicare and Medicaid Services (CMS) to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug, Aduhelm,” Secretary Becerra stated. “With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation.”

As the Lord Leads, Pray with Us…

  • For Secretary Becerra in his goal to make science-backed treatment accessible.
  • For President Biden as he pushes to mitigate public access to the experimental drug Aduhelm. 
  • That scientists would be granted clarity as they continue to research the effects of this potential treatment for Alzheimers.

Sources: The Hill, AP


Back to top